大多数CKD病人从严格的血压控制、降低心脏和大脑风险中获益更多,尽管副作用机会较大。 Most CKD patients benefit more from strict blood pressure control, lowering heart and brain risks despite higher side effect chances.

对SPRINT试验进行的一项新分析发现,几乎所有患有慢性肾病(CKD)的成年人都比标准的低于140毫米汞的严格的静脉血压目标(低于120毫米)受益更多,100%显示在将健康收益列为优先事项时净收益,90%显示在昏倒或住院等风险均衡的情况下净收益。 A new analysis of the SPRINT trial finds that nearly all adults with chronic kidney disease (CKD) benefit more from a strict systolic blood pressure target of less than 120 mm Hg than the standard less than 140 mm Hg, with 100% showing a net benefit when health gains are prioritized and 90% even when risks like fainting or hospitalization are balanced equally. 这项涉及2,012名CKD病人的研究表明,尽管治疗风险较高,但较先进的疾病患者在防止心脏病、死亡和认知下降方面得到了更大的保护。 The study, involving 2,012 CKD patients, showed those with more advanced disease gained greater protection against heart disease, death, and cognitive decline despite higher treatment risks. 成果支持现行准则,建议降低CKD患者的血压目标,可能有助于克服在强化治疗方面的犹豫不决。 Results support current guidelines recommending lower blood pressure targets for CKD patients and may help overcome hesitation in treatment intensification. 调查结果将在2025年ASN肾脏周上介绍。 Findings will be presented at ASN Kidney Week 2025.